Nothing Special   »   [go: up one dir, main page]

PA8606201A1 - DERIVADOS DE PIRROLO[3,4-c) PIRAZOL ACTIVOS COMO INHIBIDORES DE QUINASA, PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN - Google Patents

DERIVADOS DE PIRROLO[3,4-c) PIRAZOL ACTIVOS COMO INHIBIDORES DE QUINASA, PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN

Info

Publication number
PA8606201A1
PA8606201A1 PA20048606201A PA8606201A PA8606201A1 PA 8606201 A1 PA8606201 A1 PA 8606201A1 PA 20048606201 A PA20048606201 A PA 20048606201A PA 8606201 A PA8606201 A PA 8606201A PA 8606201 A1 PA8606201 A1 PA 8606201A1
Authority
PA
Panama
Prior art keywords
preparation
pirazol
pharmaceutical compositions
pirrolo
assets
Prior art date
Application number
PA20048606201A
Other languages
English (en)
Inventor
Daniele Fancelli
Barbara Forte
Jurgen Moll
Mario Varasi
Paolo Vianello
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of PA8606201A1 publication Critical patent/PA8606201A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

DERIVADOS DE PIRROLO [3,4-c]PIRAZOL ACTIVOS COMO INHIBIDORES DE QUINASA, PROCESO PARA SU PREPARACION Y COMPOSICIONES FAMACEUTICAS QUE LOS COMPRENDEN SE DESCRIBEN DERIVADOS DE PIRROLO [3,4.c] PIRAZOL DE FORMULA (1) Y SALES FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS, COMO SE DEFINE EN LA MEMORIA DESCRIPTIVA, PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN; LOS COMPUESTOS DE LA INVENCION PUEDEN SER UTILES, EN LA TERAPIA, EN EL TRATAMIENTO DE ENFERMEDADES ASOCIADAS CON UNA ACTIVIDAD DESREGULADA DE LA PROTEINQUINASA, COMO EL CANCER.
PA20048606201A 2003-07-09 2004-07-09 DERIVADOS DE PIRROLO[3,4-c) PIRAZOL ACTIVOS COMO INHIBIDORES DE QUINASA, PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN PA8606201A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48581403P 2003-07-09 2003-07-09

Publications (1)

Publication Number Publication Date
PA8606201A1 true PA8606201A1 (es) 2005-08-04

Family

ID=34062099

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20048606201A PA8606201A1 (es) 2003-07-09 2004-07-09 DERIVADOS DE PIRROLO[3,4-c) PIRAZOL ACTIVOS COMO INHIBIDORES DE QUINASA, PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN

Country Status (42)

Country Link
US (2) US7141568B2 (es)
EP (1) EP1644376B1 (es)
JP (1) JP4728232B2 (es)
KR (1) KR101075711B1 (es)
CN (1) CN100564380C (es)
AP (1) AP2214A (es)
AR (1) AR050045A1 (es)
AT (1) ATE480540T1 (es)
AU (1) AU2004255347B2 (es)
BR (1) BRPI0411868B8 (es)
CA (1) CA2531759C (es)
CR (1) CR8171A (es)
CY (1) CY1110832T1 (es)
DE (1) DE602004029045D1 (es)
DK (1) DK1644376T3 (es)
DO (1) DOP2004000949A (es)
EA (1) EA009462B1 (es)
EC (1) ECSP056246A (es)
ES (1) ES2349780T3 (es)
GE (1) GEP20084395B (es)
GT (2) GT200400133AA (es)
HK (1) HK1089769A1 (es)
HN (1) HN2004000232A (es)
IL (1) IL172923A (es)
IS (1) IS2843B (es)
MA (1) MA28064A1 (es)
ME (1) MEP51908A (es)
MX (1) MXPA06000362A (es)
MY (1) MY139072A (es)
NO (1) NO332361B1 (es)
NZ (1) NZ544514A (es)
PA (1) PA8606201A1 (es)
PE (1) PE20050325A1 (es)
PL (1) PL1644376T3 (es)
PT (1) PT1644376E (es)
RS (2) RS20060004A (es)
SI (1) SI1644376T1 (es)
TN (1) TNSN06009A1 (es)
TW (1) TWI343382B (es)
UA (1) UA81682C2 (es)
WO (1) WO2005005427A1 (es)
ZA (1) ZA200600095B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL213199B1 (pl) * 2000-08-10 2013-01-31 Pharmacia Italia Spa Zwiazek bicyklo-pirazolowy, sposób wytwarzania go, jego kompozycja farmaceutyczna, oraz kombinatoryczna biblioteka chemiczna
WO2005030776A1 (en) * 2003-09-23 2005-04-07 Vertex Pharmaceuticals Incorporated Pyrazolopyrrole derivatives as protein kinase inhibitors
JP2007514759A (ja) * 2003-12-19 2007-06-07 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
WO2005105788A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Indole derivatives and use thereof as kinase inhibitors
WO2006023931A2 (en) * 2004-08-18 2006-03-02 Takeda San Diego, Inc. Kinase inhibitors
EP1812439B2 (en) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
ATE512972T1 (de) 2005-01-10 2011-07-15 Pfizer Pyrrolopyrazole als wirksame kinaseinhibitoren
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
TW200808311A (en) * 2006-03-30 2008-02-16 Nerviano Medical Sciences Srl Use of a kinase inhibitor for the treatment of particular resistant tumors
WO2008017465A1 (en) * 2006-08-10 2008-02-14 F. Hoffmann-La Roche Ag Bicyclic lactam derivatives, their manufacture and use as pharmaceutical agents
EP2223925A1 (en) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP2010505962A (ja) 2006-10-09 2010-02-25 武田薬品工業株式会社 キナーゼ阻害剤
CN101588800B (zh) * 2006-11-03 2012-01-04 内尔维阿诺医学科学有限公司 给药抗肿瘤化合物的方法
CL2009001158A1 (es) * 2008-05-15 2009-10-23 Nerviano Medical Sciences Srl Compuestos derivados de los acidos carboxilicos, tales como 5,6-dihiro-4h-pirrolo[3,4-c]pirazol, furo[3,2-c]pirazol, tieno[2,3-c]pirazol, 4,5,6,7-tetrahidropirazol[4,3-c]piridina e indazol; composicion farmaceutica; y su uso en el tratamiento de trastornos proliferativos celulares asociados a la actividad de proteina quinasa alterada, tal como el cancer.
US20110129467A1 (en) 2008-07-24 2011-06-02 Nerviano Medical Sciences S.R.L. Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents
EP2344156B1 (en) * 2008-07-24 2018-10-17 Nerviano Medical Sciences S.r.l. Therapeutic combination comprising an aurora kinase inhibitor and an antineoplastic agent
US20100022553A1 (en) * 2008-07-24 2010-01-28 Nerviano Medical Sciences S.R.L. Therapeutic Combination Comprising an Aurora Kinase Inhibitor and Imatinib
KR101741168B1 (ko) 2008-12-22 2017-05-29 밀레니엄 파머슈티컬스 인코퍼레이티드 오로라 키나아제 억제제 및 항­cd 항체의 병용
WO2013088256A1 (en) 2011-12-12 2013-06-20 Dr. Reddy's Laboratories Ltd. Substituted pyrazolo[1,5-a] pyridine as tropomyosin receptor kinase (trk) inhibitors
CN104072498B (zh) * 2013-03-26 2016-12-28 沈阳药科大学 (R)‑N‑[5‑(2‑甲氧基‑2‑苯基乙酰基)‑1,4,5,6‑四氢吡咯并[3,4‑c]吡唑‑3‑基]‑4‑(4‑甲基哌嗪‑1‑基)苯甲酰胺的合成方法
EP3076963A4 (en) 2013-12-06 2017-09-13 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd30 antibodies
CA2953177C (en) 2014-06-23 2019-07-23 Dr. Reddy's Laboratories Ltd. Substituted imidazo[1,2-a]pyridine compounds useful for the treatment of pain
JP6787314B2 (ja) 2015-06-15 2020-11-18 宇部興産株式会社 置換ジヒドロピロロピラゾール誘導体
WO2017015316A1 (en) 2015-07-21 2017-01-26 Millennium Pharmaceuticals, Inc. Administration of aurora kinase inhibitor and chemotherapeutic agents
CN107337674B (zh) * 2016-04-29 2019-09-20 江苏吉贝尔药业股份有限公司 用于dpp-iv抑制剂的四氢吡喃胺衍生物、其药物组合物和制剂以及用途
WO2019195658A1 (en) 2018-04-05 2019-10-10 Dana-Farber Cancer Institute, Inc. Sting levels as a biomarker for cancer immunotherapy
WO2021041532A1 (en) 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
CN113563346A (zh) * 2021-08-19 2021-10-29 守恒(厦门)医疗科技有限公司 吡咯[3,4-c]并吡唑二酰胺类衍生物及其在抗肿瘤药物中的应用
WO2023196959A1 (en) 2022-04-07 2023-10-12 Eli Lilly And Company Process for making a kras g12c inhibitor
WO2023196887A1 (en) 2022-04-08 2023-10-12 Eli Lilly And Company Method of treatment including kras g12c inhibitors and aurora a inhibitors
US20240108618A1 (en) 2022-06-30 2024-04-04 Eli Lilly And Company Kras g12c inhibitor dosing regimens

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2717380B1 (fr) * 1994-03-15 1996-04-26 Oreal Compositions cosmétiques contenant un mélange synergétique de polymères conditionneurs.
GB9911053D0 (en) 1999-05-12 1999-07-14 Pharmacia & Upjohn Spa 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
DE19932144A1 (de) * 1999-07-09 2001-01-11 Basf Ag Mikrokapselzubereitungen und Mikrokapseln enthaltende Wasch- und Reinigungsmittel
US6387900B1 (en) 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
US7034049B1 (en) 1999-08-12 2006-04-25 Pharmacia Italia S.P.A. 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents
PL213199B1 (pl) 2000-08-10 2013-01-31 Pharmacia Italia Spa Zwiazek bicyklo-pirazolowy, sposób wytwarzania go, jego kompozycja farmaceutyczna, oraz kombinatoryczna biblioteka chemiczna
FR2815032B1 (fr) 2000-10-10 2003-08-08 Pf Medicament Nouveaux derives d'aminophenyle piperazine ou d'amino phenyle piperide inhibiteurs de proteines prenyl transferase ainsi que leurs preparations
WO2002048114A1 (en) 2000-11-27 2002-06-20 Pharmacia Italia S.P.A. Phenylacetamido- pyrazole derivatives and their use as antitumor agents
NZ527767A (en) 2001-01-26 2004-11-26 Pharmacia Italia S Chromane derivatives, process for their preparation and their use as antitumor agents
EP1432416B1 (en) 2001-09-26 2011-01-19 Pfizer Italia S.r.l. Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
BR0312924A (pt) 2002-07-25 2005-07-12 Pharmacia Italia Spa Biciclo-pirazóis ativos como inibidores de quinase, processo para sua preparação e composições farmacêuticas compreendendo os mesmos

Also Published As

Publication number Publication date
MY139072A (en) 2009-08-28
CN1820009A (zh) 2006-08-16
NO332361B1 (no) 2012-09-03
JP2009513525A (ja) 2009-04-02
US20060276471A1 (en) 2006-12-07
US20050032839A1 (en) 2005-02-10
CA2531759A1 (en) 2005-01-20
EP1644376B1 (en) 2010-09-08
HN2004000232A (es) 2011-01-17
AU2004255347A1 (en) 2005-01-20
GT200400133A (es) 2005-04-18
ECSP056246A (es) 2006-04-19
CR8171A (es) 2006-08-09
IS2843B (is) 2013-08-15
BRPI0411868B1 (pt) 2019-11-12
AU2004255347B2 (en) 2010-04-08
AR050045A1 (es) 2006-09-27
PT1644376E (pt) 2010-09-24
MEP51908A (en) 2011-05-10
PL1644376T3 (pl) 2011-03-31
GT200400133AA (es) 2007-07-10
AP2006003480A0 (en) 2006-02-28
SI1644376T1 (sl) 2010-11-30
DE602004029045D1 (de) 2010-10-21
CY1110832T1 (el) 2015-06-10
EP1644376A1 (en) 2006-04-12
BRPI0411868A (pt) 2006-08-08
TWI343382B (en) 2011-06-11
TNSN06009A1 (fr) 2007-10-03
AP2214A (en) 2011-03-04
IL172923A0 (en) 2006-06-11
DK1644376T3 (da) 2011-01-03
ATE480540T1 (de) 2010-09-15
ZA200600095B (en) 2007-01-31
ES2349780T3 (es) 2011-01-11
EA200600209A1 (ru) 2006-06-30
RS52155B (en) 2012-08-31
NZ544514A (en) 2009-07-31
PE20050325A1 (es) 2005-05-17
WO2005005427A1 (en) 2005-01-20
CA2531759C (en) 2013-04-02
BRPI0411868B8 (pt) 2021-05-25
US7141568B2 (en) 2006-11-28
MA28064A1 (fr) 2006-08-01
GEP20084395B (en) 2008-06-10
KR20060033001A (ko) 2006-04-18
CN100564380C (zh) 2009-12-02
EA009462B1 (ru) 2007-12-28
DOP2004000949A (es) 2005-01-15
UA81682C2 (en) 2008-01-25
NO20060113L (no) 2006-04-05
HK1089769A1 (en) 2006-12-08
IL172923A (en) 2011-09-27
RS20060004A (en) 2008-06-05
US7582628B2 (en) 2009-09-01
IS8192A (is) 2005-12-22
MXPA06000362A (es) 2006-03-28
TW200510385A (en) 2005-03-16
KR101075711B1 (ko) 2011-10-21
JP4728232B2 (ja) 2011-07-20

Similar Documents

Publication Publication Date Title
PA8606201A1 (es) DERIVADOS DE PIRROLO[3,4-c) PIRAZOL ACTIVOS COMO INHIBIDORES DE QUINASA, PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN
DE602004017194D1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
ECSP056194A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa
ECSP066767A (es) Derivados 1h-tieno[2,3-c]pirazol útiles como inhibidores de quinasa
MXPA06000302A (es) Derivados de pirazolil-indol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden.
DOP2009000155A (es) Derivados de hetero-pentaciclo-fenilo fusionados, composicion farmaceutica que los comprende y usos para preparar un medicamento util para el tratamiento de una condicion mediada por p38
PA8587101A1 (es) Nuevos derivados de dihidropirimido [4,5-d] pirimidinona sustituida por amiino, fabricacion y uso de los mismos como agentes farmaceuticos
NO20061506L (no) Heterocykliske inhibitorer av MEK og fremgangsmater for anvendelse derav
EA200970595A1 (ru) Производные замещенных индазолов, активные в качестве ингибиторов киназ
PA8680701A1 (es) Derivados de oxindol
BRPI0413438A (pt) derivados de pirimidilpirrol ativos como inibidores de cinase
UY28271A1 (es) Compuestos químicos
GB0222514D0 (en) Organic compounds
UY28536A1 (es) Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos.
UY28356A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparaciones de los mismos y sus usos
NO20055891L (no) Kinazolinderivater som aurorakinaseinhibitorer
NO20043792L (no) New heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in medicine
UY28357A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparación de los mismos y sus usos
PT1109560E (pt) Compostos uteis como inidores de aicarft
UY28535A1 (es) Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos.
UY28537A1 (es) Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos.
ECSP056190A (es) Compuestos utiles en la terapia de la enfermedad de alzheimer y formulaciones que los contienen
UY28409A1 (es) Derivados de pirrolo (3,4-c) pirazol activos como inhibidores de quinasa, proceso para su preparación y composiciones farmaceuticas que los comprenden
CU23566B7 (es) Derivados de pirrolo [3,4-c]pirazol activos como inhibidores de quinasa
UY29043A1 (es) Derivados de diarilmetil piperazina, preparaciones de los mismos y usos de los mismos